今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

境外机构非法跨境证券交易乱象：投资者需提高警惕，加强风险防范

近年来，随着互联网技术的快速发展，跨境证券交易日益便捷，为投资者提供了更多选择和机会。然而，一些境外机构利用互联网平台，非法向中国境内投资者提供跨境证券交易服务，扰乱了正常的市场秩序，侵害了投资者合法权益。

这些境外机构的常见违法行为包括：

• 未经中国证监会批准，非法从事跨境证券业务；
• 通过虚假宣传、误导性陈述等手段，诱骗投资者开户交易；
• 利用非法手段获取投资者身份信息、交易账户等敏感信息；
• 操纵市场价格，损害投资者利益；
• 未履行投资者适当性审查义务，向不符合条件的投资者提供服务；
• 无法保障投资者资金安全，存在挪用、侵占投资者资金的风险。

投资者参与境外证券交易面临的风险：

• 境外机构可能不遵守中国法律法规，投资者合法权益难以得到有效保护；
• 境外市场信息不对称，投资者难以了解相关证券的真实情况；
• 境外交易平台可能存在技术故障、交易欺诈等风险；
• 投资者资金可能因汇率波动而遭受损失。

中国证监会多次发布风险提示，提醒投资者谨慎参与境外证券交易。投资者应选择合法持牌机构，了解交易规则和风险，审慎投资决策，加强风险防范。

以下是一些防范境外机构非法跨境证券交易风险的建议：

• 选择经中国证监会批准的境外证券机构进行交易；
• 仔细核验境外机构的资质信息；
• 了解境外证券市场相关法律法规和交易规则；
• 索取并仔细阅读相关投资材料，充分了解投资产品的风险；
• 审慎评估自身风险承受能力，选择适合的投资产品；
• 保留相关交易凭证，依法维护自身合法权益。

投资者应树立理性投资理念，远离高收益、高风险的非法跨境证券交易活动，共同维护证券市场的健康发展。